These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 28123067)

  • 1. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.
    DeVos SL; Miller RL; Schoch KM; Holmes BB; Kebodeaux CS; Wegener AJ; Chen G; Shen T; Tran H; Nichols B; Zanardi TA; Kordasiewicz HB; Swayze EE; Bennett CF; Diamond MI; Miller TM
    Sci Transl Med; 2017 Jan; 9(374):. PubMed ID: 28123067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo.
    DeVos SL; Corjuc BT; Commins C; Dujardin S; Bannon RN; Corjuc D; Moore BD; Bennett RE; Jorfi M; Gonzales JA; Dooley PM; Roe AD; Pitstick R; Irimia D; Frosch MP; Carlson GA; Hyman BT
    Brain; 2018 Jul; 141(7):2194-2212. PubMed ID: 29733334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy.
    Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M
    Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of mouse models to study cell-to-cell transmission of pathological tau.
    Narasimhan S; Lee VMY
    Methods Cell Biol; 2017; 141():287-305. PubMed ID: 28882308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
    Köhler C; Fuhr V; Dinekov M
    Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model.
    Houben S; Leroy K; Ando K; Yilmaz Z; Widomski C; Buée L; Brion JP
    Neurobiol Dis; 2019 Jul; 127():131-141. PubMed ID: 30818066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
    Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
    J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
    Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
    Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
    Shi Y; Yamada K; Liddelow SA; Smith ST; Zhao L; Luo W; Tsai RM; Spina S; Grinberg LT; Rojas JC; Gallardo G; Wang K; Roh J; Robinson G; Finn MB; Jiang H; Sullivan PM; Baufeld C; Wood MW; Sutphen C; McCue L; Xiong C; Del-Aguila JL; Morris JC; Cruchaga C; ; Fagan AM; Miller BL; Boxer AL; Seeley WW; Butovsky O; Barres BA; Paul SM; Holtzman DM
    Nature; 2017 Sep; 549(7673):523-527. PubMed ID: 28959956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
    Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
    Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
    J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy.
    Vagnozzi AN; Giannopoulos PF; Praticò D
    Transl Psychiatry; 2017 Dec; 7(12):1288. PubMed ID: 29249809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau Seeding Mouse Models with Patient Brain-Derived Aggregates.
    Robert A; Schöll M; Vogels T
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau exhibits unique seeding properties in globular glial tauopathy.
    Chung DC; Carlomagno Y; Cook CN; Jansen-West K; Daughrity L; Lewis-Tuffin LJ; Castanedes-Casey M; DeTure M; Dickson DW; Petrucelli L
    Acta Neuropathol Commun; 2019 Mar; 7(1):36. PubMed ID: 30845985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
    Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
    Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex Impact on Tau-Aggregation and Postsynaptic Protein Levels in the P301L Mouse Model of Tauopathy.
    Buccarello L; Grignaschi G; Castaldo AM; Di Giancamillo A; Domeneghini C; Melcangi RC; Borsello T
    J Alzheimers Dis; 2017; 56(4):1279-1292. PubMed ID: 28157099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
    Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice.
    Yukawa K; Yamamoto-Mcguire S; Cafaro L; Hong C; Kamme F; Ikezu T; Ikezu S
    Acta Neuropathol Commun; 2023 Oct; 11(1):166. PubMed ID: 37853497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.